TD Cowen analyst Phil Nadeau maintains $Biogen (BIIB.US)$ with a buy rating, and maintains the target price at $275.
According to TipRanks data, the analyst has a success rate of 46.9% and a total average return of 6.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
Biogen's approach to counter the decline of its core franchise involves focusing on developing treatments for conditions with a high unmet medical need, despite the challenging nature of these indications. The company's pipeline is perceived to carry a higher clinical risk compared to its major biotech counterparts, which simultaneously offers considerable potential value.
The firm indicated that Biogen's collaborator's successful appeal to the EMA's CHMP for another look at the MAA for a treatment in amyloid-positive early Alzheimer's disease resulted in a favorable recommendation, albeit with an exclusion for a certain genotype. This adjustment is believed to make the proposal more agreeable to the European Commission, with an anticipated approval decision due within 67 days.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Phil Nadeau維持$渤健公司 (BIIB.US)$買入評級，維持目標價275美元。
根據TipRanks數據顯示，該分析師近一年總勝率為46.9%，總平均回報率為6.5%。
此外，綜合報道，$渤健公司 (BIIB.US)$近期主要分析師觀點如下：
渤健公司應對核心產品系列下滑的方法包括專注於開發治療存在高度醫療需求的疾病，儘管這些指標具有挑戰性。該公司的產品管道被認爲相比其主要生物技術對手存在更高的臨床風險，同時也提供了相當大的潛在價值。
該公司表示，渤健公司的合作伙伴成功向歐洲藥品管理局CHMP上訴，要求重新審議關於早期阿爾茨海默病澱粉樣陽性療法的歐洲上市許可申請，結果獲得了有利意見，儘管對某一基因型進行了排除。這一調整被認爲將使提案更符合歐洲委員會的意願，預計將在67天內做出批准決定。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
